You have 9 free searches left this month | for more free features.

Humanized Monoclonal Antibody 3F8 (Hu3F8)

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Recurrent Osteosarcoma Trial in Los Angeles, New York, Houston (humanized anti-GD2 antibody, GM-CSF)

Recruiting
  • Recurrent Osteosarcoma
  • humanized anti-GD2 antibody
  • GM-CSF
  • Los Angeles, California
  • +2 more
Dec 22, 2022

Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in Columbus (procedure, drug, biological)

Not yet recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • HER2-Negative Breast Carcinoma
  • Biospecimen Collection
  • +5 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Aug 30, 2023

Neuroblastoma Trial in New York (Humanized 3F8 Monoclonal Antibody (Hu3F8))

Active, not recruiting
  • Neuroblastoma
  • Humanized 3F8 Monoclonal Antibody (Hu3F8)
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Aug 24, 2021

Neuroblastoma Trial in New York (3F8 Monoclonal Antibody Combined with Interleukin-2)

Completed
  • Neuroblastoma
  • 3F8 Monoclonal Antibody Combined with Interleukin-2
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 26, 2021

Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers Trial in New York (Humanized 3F8 Bispecific Antibody, Blood draw)

Terminated
  • Neuroblastoma
  • +2 more
  • Humanized 3F8 Bispecific Antibody
  • Blood draw
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 11, 2022

Melanoma, Neuroblastoma, Sarcoma Trial in New York (124I-Humanized 3F8)

Active, not recruiting
  • Melanoma
  • +2 more
  • 124I-Humanized 3F8
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Dec 1, 2022

Neuroblastoma Trial in New York (Hu3F8 With GM-CSF)

Active, not recruiting
  • Neuroblastoma
  • Hu3F8 With GM-CSF
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 2, 2022

Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)

Recruiting
  • Neuroblastoma
  • Naxitamab monotherapy
  • +6 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 31, 2023

Neuroblastoma, High-Risk Trial in New York (cyclophosphamide, NK cells, hu3F8)

Active, not recruiting
  • Neuroblastoma
  • High-Risk
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 14, 2022

Neuroblastoma Trial in New York (Hu3F8, GM-CSF, Isotretinoin)

Active, not recruiting
  • Neuroblastoma
  • Hu3F8
  • +2 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 1, 2022

Neuroblastoma Trial in New York (anti-GD2 murine IgG3 mAb 3F8)

Completed
  • Neuroblastoma
  • anti-GD2 murine IgG3 monoclonal antibody 3F8
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Apr 21, 2022

Neuroblastoma Trial in New York (beta-glucan, mAb 3F8, immunohistochemistry staining method)

Completed
  • Neuroblastoma
  • beta-glucan
  • +3 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 4, 2022

Ovarian Cancer Trial in New York (90Y-hu3S193, 111In-hu3S193)

Completed
  • Ovarian Cancer
  • 90Y-hu3S193
  • 111In-hu3S193
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Ovarian Cancer Trial in New York (Monoclonal antibody hu3S193)

Terminated
  • Ovarian Cancer
  • Monoclonal antibody hu3S193
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Colorectal Cancer Trial in New York (mAb hu3S193)

Terminated
  • Colorectal Cancer
  • monoclonal antibody hu3S193
  • New York, New York
    Memorial Sloan-Kettering Cancer Center
Oct 3, 2022

Brain and CNS Tumors, Intraocular Melanoma, Lung Cancer Trial in New York (genetic, other, radiation)

Active, not recruiting
  • Brain and Central Nervous System Tumors
  • +9 more
  • DNA analysis
  • +4 more
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 28, 2021

Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint

Recruiting
  • Metastatic Lung Non-Small Cell Carcinoma
  • +4 more
  • Necitumumab
  • +4 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Jan 5, 2023

Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma, Refractory Nodular

Not yet recruiting
  • Nodular Lymphocyte Predominant Hodgkin Lymphoma
  • +2 more
  • Biopsy
  • +9 more
  • (no location specified)
Jun 1, 2023

Neuroblastoma Trial in Worldwide (GM-CSF + Naxitamab)

Recruiting
  • Neuroblastoma
  • GM-CSF + Naxitamab
  • Gainesville, Florida
  • +22 more
Aug 29, 2022

Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8 Trial in Chicago (procedure,

Not yet recruiting
  • Prostate Adenocarcinoma
  • +3 more
  • Biopsy of Prostate
  • +6 more
  • Chicago, Illinois
    Northwestern University
May 9, 2023

Neuroblastoma (NB) Trial in New York (Irinotecan, temozolomide, Hu3F8)

Active, not recruiting
  • Neuroblastoma (NB)
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Oct 19, 2021

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial

Recruiting
  • Anatomic Stage I Breast Cancer AJCC v8
  • +19 more
  • pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 1, 2022

Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell

Not yet recruiting
  • Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
  • +2 more
  • Biopsy
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 28, 2023

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8

Recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +12 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 16, 2022

Classic Hodgkin Lymphoma Trial (procedure, biological, drug, other, radiation)

Not yet recruiting
  • Classic Hodgkin Lymphoma
  • Biospecimen Collection
  • +19 more
  • (no location specified)
Jan 6, 2023